IS8291A - Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar - Google Patents

Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar

Info

Publication number
IS8291A
IS8291A IS8291A IS8291A IS8291A IS 8291 A IS8291 A IS 8291A IS 8291 A IS8291 A IS 8291A IS 8291 A IS8291 A IS 8291A IS 8291 A IS8291 A IS 8291A
Authority
IS
Iceland
Prior art keywords
dithionic
pyrrole
deliver
derivatives
receptor antagonists
Prior art date
Application number
IS8291A
Other languages
English (en)
Inventor
Holm Patrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8291A publication Critical patent/IS8291A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IS8291A 2003-07-11 2006-02-09 Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar IS8291A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
IS8291A true IS8291A (is) 2006-02-09

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8291A IS8291A (is) 2003-07-11 2006-02-09 Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar

Country Status (25)

Country Link
US (1) US20060189663A1 (is)
EP (1) EP1646625B1 (is)
JP (1) JP2007521313A (is)
KR (1) KR20060034284A (is)
CN (1) CN100478340C (is)
AR (1) AR045720A1 (is)
AT (1) ATE399776T1 (is)
AU (1) AU2004256000B2 (is)
BR (1) BRPI0412479A (is)
CA (1) CA2532068A1 (is)
CO (1) CO5640134A2 (is)
DE (1) DE602004014772D1 (is)
ES (1) ES2308205T3 (is)
GB (1) GB0316237D0 (is)
IL (1) IL172759A0 (is)
IS (1) IS8291A (is)
MX (1) MXPA06000447A (is)
NO (1) NO20060080L (is)
RU (1) RU2006102129A (is)
SA (1) SA04250203B1 (is)
TW (1) TW200507836A (is)
UA (1) UA82108C2 (is)
UY (1) UY28407A1 (is)
WO (1) WO2005005416A1 (is)
ZA (1) ZA200600229B (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
JP2008526841A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓x受容体調節因子としてのイソチアゾール−3(2h)−オン1,1−ジオキシドのアニリン系誘導体
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
JP4936476B2 (ja) * 2005-06-28 2012-05-23 第一三共株式会社 Lxrリガンドの試験方法
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
AU2011299703A1 (en) 2010-09-07 2013-04-11 Snu R&Db Foundation Sesterterpene compounds and use thereof
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels

Also Published As

Publication number Publication date
JP2007521313A (ja) 2007-08-02
SA04250203B1 (ar) 2008-02-25
IL172759A0 (en) 2006-04-10
UA82108C2 (uk) 2008-03-11
CO5640134A2 (es) 2006-05-31
WO2005005416A1 (en) 2005-01-20
CN1820003A (zh) 2006-08-16
ZA200600229B (en) 2007-04-25
TW200507836A (en) 2005-03-01
KR20060034284A (ko) 2006-04-21
AR045720A1 (es) 2005-11-09
BRPI0412479A (pt) 2006-09-19
RU2006102129A (ru) 2006-08-27
MXPA06000447A (es) 2006-04-07
EP1646625B1 (en) 2008-07-02
CN100478340C (zh) 2009-04-15
UY28407A1 (es) 2005-02-28
GB0316237D0 (en) 2003-08-13
ES2308205T3 (es) 2008-12-01
EP1646625A1 (en) 2006-04-19
US20060189663A1 (en) 2006-08-24
AU2004256000B2 (en) 2007-07-26
NO20060080L (no) 2006-02-08
HK1088318A1 (en) 2006-11-03
AU2004256000A1 (en) 2005-01-20
ATE399776T1 (de) 2008-07-15
CA2532068A1 (en) 2005-01-20
DE602004014772D1 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
IS8466A (is) 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
IS8313A (is) Sýklískar afleiður sem stillar kemókínviðtakavirkni
IS7697A (is) Pýrimídýlsúlfónamíðafleiður sem miðlar flakkboðaviðtaka
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
AP2006003566A0 (en) Muscarinic Acetycholine receptor antagonists.
DK1720859T3 (da) Chemokinreceptorantagonister
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL179737A0 (en) Indole derivatives as histamine receptor antagonists
ZA200610666B (en) Piperidine derivatives as NK, antagonists
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
IL173512A0 (en) Cyclopropyl derivatives as nk3 receptor antagonists
IS8293A (is) Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX
IL171930A0 (en) Imidazole derivatives as glutamate receptor antagonists
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
IS2456B (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
ITMI20031292A1 (it) Derivati biciclici nk-2 antagonisti selettivi.
IS8172A (is) N-úreidóalkýl-piperídín sem stillar kemókínviðtakavirkni
HU0501169D0 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists